Navigating the Complexities of Immunotherapy for Mesothelioma: Insights for Patients and Caregivers

ByHolly Zink
Navigating the Complexities of Immunotherapy for Mesothelioma: Insights for Patients and Caregivers

Mesothelioma is a rare, aggressive cancer that poses challenges for patients and caregivers. Recently, immune checkpoint inhibitors have brought hope for its treatment.

However, new data from Australia has raised questions about their effectiveness and safety. Patients and caregivers must understand immunotherapy’s details and its impact on treatment decisions.

A new article from the Journal of Thoracic Oncology shows the real-world results from Australia on immunotherapy for mesothelioma.

Understanding the Real-World Implications

Mesothelioma treatment has changed with the approval of immune checkpoint inhibitors, like ipilimumab and nivolumab. Clinical trials show promise. However, real-world evidence is more complex.

Real-world evidence highlights high drug discontinuation rates, serious side effects, and the need for more treatments. Thus, it’s crucial to carefully consider the benefits and risks of immunotherapy for each patient.

The histological subtype of mesothelioma is crucial in immunotherapy responses. Some patients benefit, but others face severe side effects without clear outcomes.

For instance, those with the epithelioid subtype often experience adverse events with no survival benefits. Meanwhile, non-epithelioid patients may see some improvement. However, more research is needed to understand these differences and identify the best candidates for immunotherapy.

The Importance of Informed Decision-Making

Patients or caregivers should openly discuss immunotherapy’s risks and benefits with healthcare providers. Not everyone is suited to immune checkpoint inhibitors, despite their hope for some. Factors like health, goals, and cancer type are crucial in choosing treatment.

New clinical trials now check the safety and effectiveness of immunotherapy in various patient groups. Their goal is to show how to best use immunotherapy for mesothelioma.

Mesothelioma treatment, especially immunotherapy, is complex. It can be tough for patients and caregivers. But, staying informed, asking questions, and working closely with doctors help make the right decisions. These decisions should focus on the patient’s health.

The future may seem uncertain but, ongoing research is promising. Research will lead to better mesothelioma treatments, improving outcomes for patients globally.

Source:

Gray, Steven G., Tomer Meirson, and Luciano Mutti. “Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma.” Journal of Thoracic Oncology 19, no. 4 (April 1, 2024): 541–46. https://doi.org/10.1016/j.jtho.2024.01.016.

 

 

Similar Posts

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    ByAlex Strauss

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • | | |

    Mesothelioma Nurses Ready for New Cases in Australia

    ByAlex Strauss

    Australia is bracing for an expected new wave of mesothelioma cases in the next decade and the Lung Foundation of Australia is taking action now to get ready. The Foundation has paid for ten nurses from around the country to receive specialized training in helping patients and families cope with mesothelioma. The nurses, who have recently completed the training, are now equipped to lead treatment planning for these complex cancer patients and to help other nurses do the same. Pleural mesothelioma is an aggressive cancer that occurs in the lining around the lungs. It is caused by exposure to asbestos dust, a toxin that was once alarmingly prevalent in Australia where it was mined and heavily used in construction. Because…

  • | |

    Mesothelioma Study Finds New Treatment Target

    ByAlex Strauss

    Immunotherapy, which involves reprogramming T-cells to find and attack cancer cells, is one of the fastest-growing areas of cancer research. One of the biggest challenges of immunotherapy is how to harness the power of T-cells against cancer without also turning them against healthy cells. A new study conducted in Switzerland and published in the Journal of Translational Medicine addressed the problem by reprogramming T-cells to recognize and attack mesothelioma cells that express a specific protein. Fibroblast Activation Protein (FAP) is expressed on the surface of tumor-associated fibroblast cells which are found in the connective tissue of mesothelioma tumors. FAP is also found in mesothelioma cells and may play a role in the start of cancer, as well as the growth…

  • | |

    Mesothelioma Study Could Improve Immunotherapy

    ByAlex Strauss

    Scientists have made an important discovery about a component of the immune system that could have an impact on mesothelioma, one of the rarest and most aggressive cancers. Although mesothelioma is rare, it claims about 2,500 lives in the U.S. annually. Scientists around the globe are searching for a method to keep this cancer from spreading across the membranes that surround the lungs or line the abdomen. As mesothelioma tumors on these membranes grow larger, the likelihood that the cancer will spread to the lungs or other internal organs increases. The immune system is designed to help stop the spread of invaders or out-of-control cancer cells. One immune cell, the Natural Killer or NK cell, is known to exert an anti-tumor effect…

  • | | |

    Australian Electricians Fear Mesothelioma Risk

    ByAlex Strauss

    Calling the modification of electrical meter boxes a “game changer”, an official from Australia’s largest electricians union says workers should refuse to do it until the dangerous boxes have been inspected. Allen Hicks, Assistant National Secretary of the Electrical Trades Union, told the Sydney Morning Herald that asbestos-containing meter boxes are being modified more frequently because of renovations and that too many workers are not adequately protected against mesothelioma and other asbestos related diseases. The warning, which centers on the meter boxes in homes built before 1983, was issued after a New South Wales electrical company instructed its workers to wear masks around the boxes to minimize asbestos and mesothelioma risk. When the Electrical Trades Union learned of the warning, they advised…

  • | |

    Mesothelioma Vaccine Enters Phase 2 Testing

    ByAlex Strauss

    The makers of a new cancer vaccine say they have enrolled the first mesothelioma patients in a study that will combine their drug with chemotherapy against this virulent cancer. The drug, currently known as CRS-207, is manufactured by Aduro Bio Tech, Inc. According to a company press release, CRS-207 is based on an attenuated (made less potent) version of Listeria monocytogenes, bacteria found in soil and water than can cause the food borne illness, Listeriosis. To make CRS-207, scientists at Aduro genetically modified the Listeria monocytogenes in order to produce a powerful immune response against cells that produce mesothelin. Mesothelin is a tumor-associated antigen produced by several types of cancer cells, including mesothelioma cells. Because it works in conjunction with the body’s…